CD 45 RA , a specific marker for leukaemia stem cell sub‐populations in acute myeloid leukaemia
Chemotherapy resistant leukaemic stem cells ( LSC ) are thought to be responsible for relapses after therapy in acute myeloid leukaemia ( AML ). Flow cytometry can discriminate CD 34 + CD 38 − LSC and normal haematopoietic stem cells ( HSC ) by using aberrant expression of markers and scatter proper...
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2016-04, Vol.173 (2), p.219-235 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 235 |
|---|---|
| container_issue | 2 |
| container_start_page | 219 |
| container_title | British journal of haematology |
| container_volume | 173 |
| creator | Kersten, Bas Valkering, Matthijs Wouters, Rolf van Amerongen, Rosa Hanekamp, Diana Kwidama, Zinia Valk, Peter Ossenkoppele, Gert Zeijlemaker, Wendelien Kaspers, Gertjan Cloos, Jacqueline Schuurhuis, Gerrit J. |
| description | Chemotherapy resistant leukaemic stem cells (
LSC
) are thought to be responsible for relapses after therapy in acute myeloid leukaemia (
AML
). Flow cytometry can discriminate
CD
34
+
CD
38
−
LSC
and normal haematopoietic stem cells (
HSC
) by using aberrant expression of markers and scatter properties. However, not all
LSC
can be identified using currently available markers, so new markers are needed.
CD
45
RA
is expressed on leukaemic cells in the majority of
AML
patients. We investigated the potency of
CD
45
RA
to specifically identify
LSC
and
HSC
and improve
LSC
quantification. Compared to our best other markers (
CLL
‐1, also termed
CLEC
12A,
CD
33 and
CD
123),
CD
45
RA
was the most reliable marker. Patients with high percentages (>90%) of
CD
45
RA
on
CD
34
+
CD
38
−
LSC
have 1·69‐fold higher scatter values compared to
HSC
(
P
|
| doi_str_mv | 10.1111/bjh.13941 |
| format | Article |
| fullrecord | <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1111_bjh_13941</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1111_bjh_13941</sourcerecordid><originalsourceid>FETCH-LOGICAL-c741-29692ba8c6d72352e0084598c79a48772e5e4906c6b98bc6daaae22972a82cfd3</originalsourceid><addsrcrecordid>eNpFkM1KxDAUhYMoWEcXvsHdCnZM0rRJlkN1VBgQZPblNr3FzLTT0rSL2fkIPqNPYv0Bz-YszjkX7sfYteBLMeuu3L0tRWKVOGGRSLI0lkKJUxZxznUsuDLn7CKEHeci4amIGOb3oFJ4XcEtIISenK-9gxaHPQ1QdwM0NO2RWj-nI7XgqGkgTOXn-0ff9VODo-8OAfwB0E0jQXukpvPV_-ySndXYBLr68wXbrh-2-VO8eXl8zleb2GklYmkzK0s0Lqu0TFJJnBuVWuO0RWW0lpSSsjxzWWlNObcQkaS0WqKRrq6SBbv5PeuGLoSB6qIf_PzGsRC8-EZTzGiKHzTJF2b_Vts</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>CD 45 RA , a specific marker for leukaemia stem cell sub‐populations in acute myeloid leukaemia</title><source>Wiley Online Library</source><source>Wiley Online Library Journals</source><creator>Kersten, Bas ; Valkering, Matthijs ; Wouters, Rolf ; van Amerongen, Rosa ; Hanekamp, Diana ; Kwidama, Zinia ; Valk, Peter ; Ossenkoppele, Gert ; Zeijlemaker, Wendelien ; Kaspers, Gertjan ; Cloos, Jacqueline ; Schuurhuis, Gerrit J.</creator><creatorcontrib>Kersten, Bas ; Valkering, Matthijs ; Wouters, Rolf ; van Amerongen, Rosa ; Hanekamp, Diana ; Kwidama, Zinia ; Valk, Peter ; Ossenkoppele, Gert ; Zeijlemaker, Wendelien ; Kaspers, Gertjan ; Cloos, Jacqueline ; Schuurhuis, Gerrit J.</creatorcontrib><description>Chemotherapy resistant leukaemic stem cells (
LSC
) are thought to be responsible for relapses after therapy in acute myeloid leukaemia (
AML
). Flow cytometry can discriminate
CD
34
+
CD
38
−
LSC
and normal haematopoietic stem cells (
HSC
) by using aberrant expression of markers and scatter properties. However, not all
LSC
can be identified using currently available markers, so new markers are needed.
CD
45
RA
is expressed on leukaemic cells in the majority of
AML
patients. We investigated the potency of
CD
45
RA
to specifically identify
LSC
and
HSC
and improve
LSC
quantification. Compared to our best other markers (
CLL
‐1, also termed
CLEC
12A,
CD
33 and
CD
123),
CD
45
RA
was the most reliable marker. Patients with high percentages (>90%) of
CD
45
RA
on
CD
34
+
CD
38
−
LSC
have 1·69‐fold higher scatter values compared to
HSC
(
P
< 0·001), indicating a more mature
CD
34
+
CD
38
−
phenotype. Patients with low (<10%) or intermediate (10–90%)
CD
45
RA
expression on
LSC
showed no significant differences to
HSC
(1·12‐ and 1·15‐fold higher,
P
= 0·31 and
P
= 0·44, respectively).
CD
45
RA
‐positive
LSC
tended to represent more favourable cytogenetic/molecular markers. In conclusion,
CD
45
RA
contributes to more accurate
LSC
detection and is recommended for inclusion in stem cell tracking panels.
CD
45
RA
may contribute to define new
LSC
‐specific therapies and to monitor effects of anti‐
LSC
treatment.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.13941</identifier><language>eng</language><ispartof>British journal of haematology, 2016-04, Vol.173 (2), p.219-235</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c741-29692ba8c6d72352e0084598c79a48772e5e4906c6b98bc6daaae22972a82cfd3</citedby><cites>FETCH-LOGICAL-c741-29692ba8c6d72352e0084598c79a48772e5e4906c6b98bc6daaae22972a82cfd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids></links><search><creatorcontrib>Kersten, Bas</creatorcontrib><creatorcontrib>Valkering, Matthijs</creatorcontrib><creatorcontrib>Wouters, Rolf</creatorcontrib><creatorcontrib>van Amerongen, Rosa</creatorcontrib><creatorcontrib>Hanekamp, Diana</creatorcontrib><creatorcontrib>Kwidama, Zinia</creatorcontrib><creatorcontrib>Valk, Peter</creatorcontrib><creatorcontrib>Ossenkoppele, Gert</creatorcontrib><creatorcontrib>Zeijlemaker, Wendelien</creatorcontrib><creatorcontrib>Kaspers, Gertjan</creatorcontrib><creatorcontrib>Cloos, Jacqueline</creatorcontrib><creatorcontrib>Schuurhuis, Gerrit J.</creatorcontrib><title>CD 45 RA , a specific marker for leukaemia stem cell sub‐populations in acute myeloid leukaemia</title><title>British journal of haematology</title><description>Chemotherapy resistant leukaemic stem cells (
LSC
) are thought to be responsible for relapses after therapy in acute myeloid leukaemia (
AML
). Flow cytometry can discriminate
CD
34
+
CD
38
−
LSC
and normal haematopoietic stem cells (
HSC
) by using aberrant expression of markers and scatter properties. However, not all
LSC
can be identified using currently available markers, so new markers are needed.
CD
45
RA
is expressed on leukaemic cells in the majority of
AML
patients. We investigated the potency of
CD
45
RA
to specifically identify
LSC
and
HSC
and improve
LSC
quantification. Compared to our best other markers (
CLL
‐1, also termed
CLEC
12A,
CD
33 and
CD
123),
CD
45
RA
was the most reliable marker. Patients with high percentages (>90%) of
CD
45
RA
on
CD
34
+
CD
38
−
LSC
have 1·69‐fold higher scatter values compared to
HSC
(
P
< 0·001), indicating a more mature
CD
34
+
CD
38
−
phenotype. Patients with low (<10%) or intermediate (10–90%)
CD
45
RA
expression on
LSC
showed no significant differences to
HSC
(1·12‐ and 1·15‐fold higher,
P
= 0·31 and
P
= 0·44, respectively).
CD
45
RA
‐positive
LSC
tended to represent more favourable cytogenetic/molecular markers. In conclusion,
CD
45
RA
contributes to more accurate
LSC
detection and is recommended for inclusion in stem cell tracking panels.
CD
45
RA
may contribute to define new
LSC
‐specific therapies and to monitor effects of anti‐
LSC
treatment.</description><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNpFkM1KxDAUhYMoWEcXvsHdCnZM0rRJlkN1VBgQZPblNr3FzLTT0rSL2fkIPqNPYv0Bz-YszjkX7sfYteBLMeuu3L0tRWKVOGGRSLI0lkKJUxZxznUsuDLn7CKEHeci4amIGOb3oFJ4XcEtIISenK-9gxaHPQ1QdwM0NO2RWj-nI7XgqGkgTOXn-0ff9VODo-8OAfwB0E0jQXukpvPV_-ySndXYBLr68wXbrh-2-VO8eXl8zleb2GklYmkzK0s0Lqu0TFJJnBuVWuO0RWW0lpSSsjxzWWlNObcQkaS0WqKRrq6SBbv5PeuGLoSB6qIf_PzGsRC8-EZTzGiKHzTJF2b_Vts</recordid><startdate>201604</startdate><enddate>201604</enddate><creator>Kersten, Bas</creator><creator>Valkering, Matthijs</creator><creator>Wouters, Rolf</creator><creator>van Amerongen, Rosa</creator><creator>Hanekamp, Diana</creator><creator>Kwidama, Zinia</creator><creator>Valk, Peter</creator><creator>Ossenkoppele, Gert</creator><creator>Zeijlemaker, Wendelien</creator><creator>Kaspers, Gertjan</creator><creator>Cloos, Jacqueline</creator><creator>Schuurhuis, Gerrit J.</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201604</creationdate><title>CD 45 RA , a specific marker for leukaemia stem cell sub‐populations in acute myeloid leukaemia</title><author>Kersten, Bas ; Valkering, Matthijs ; Wouters, Rolf ; van Amerongen, Rosa ; Hanekamp, Diana ; Kwidama, Zinia ; Valk, Peter ; Ossenkoppele, Gert ; Zeijlemaker, Wendelien ; Kaspers, Gertjan ; Cloos, Jacqueline ; Schuurhuis, Gerrit J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c741-29692ba8c6d72352e0084598c79a48772e5e4906c6b98bc6daaae22972a82cfd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kersten, Bas</creatorcontrib><creatorcontrib>Valkering, Matthijs</creatorcontrib><creatorcontrib>Wouters, Rolf</creatorcontrib><creatorcontrib>van Amerongen, Rosa</creatorcontrib><creatorcontrib>Hanekamp, Diana</creatorcontrib><creatorcontrib>Kwidama, Zinia</creatorcontrib><creatorcontrib>Valk, Peter</creatorcontrib><creatorcontrib>Ossenkoppele, Gert</creatorcontrib><creatorcontrib>Zeijlemaker, Wendelien</creatorcontrib><creatorcontrib>Kaspers, Gertjan</creatorcontrib><creatorcontrib>Cloos, Jacqueline</creatorcontrib><creatorcontrib>Schuurhuis, Gerrit J.</creatorcontrib><collection>CrossRef</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kersten, Bas</au><au>Valkering, Matthijs</au><au>Wouters, Rolf</au><au>van Amerongen, Rosa</au><au>Hanekamp, Diana</au><au>Kwidama, Zinia</au><au>Valk, Peter</au><au>Ossenkoppele, Gert</au><au>Zeijlemaker, Wendelien</au><au>Kaspers, Gertjan</au><au>Cloos, Jacqueline</au><au>Schuurhuis, Gerrit J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CD 45 RA , a specific marker for leukaemia stem cell sub‐populations in acute myeloid leukaemia</atitle><jtitle>British journal of haematology</jtitle><date>2016-04</date><risdate>2016</risdate><volume>173</volume><issue>2</issue><spage>219</spage><epage>235</epage><pages>219-235</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><abstract>Chemotherapy resistant leukaemic stem cells (
LSC
) are thought to be responsible for relapses after therapy in acute myeloid leukaemia (
AML
). Flow cytometry can discriminate
CD
34
+
CD
38
−
LSC
and normal haematopoietic stem cells (
HSC
) by using aberrant expression of markers and scatter properties. However, not all
LSC
can be identified using currently available markers, so new markers are needed.
CD
45
RA
is expressed on leukaemic cells in the majority of
AML
patients. We investigated the potency of
CD
45
RA
to specifically identify
LSC
and
HSC
and improve
LSC
quantification. Compared to our best other markers (
CLL
‐1, also termed
CLEC
12A,
CD
33 and
CD
123),
CD
45
RA
was the most reliable marker. Patients with high percentages (>90%) of
CD
45
RA
on
CD
34
+
CD
38
−
LSC
have 1·69‐fold higher scatter values compared to
HSC
(
P
< 0·001), indicating a more mature
CD
34
+
CD
38
−
phenotype. Patients with low (<10%) or intermediate (10–90%)
CD
45
RA
expression on
LSC
showed no significant differences to
HSC
(1·12‐ and 1·15‐fold higher,
P
= 0·31 and
P
= 0·44, respectively).
CD
45
RA
‐positive
LSC
tended to represent more favourable cytogenetic/molecular markers. In conclusion,
CD
45
RA
contributes to more accurate
LSC
detection and is recommended for inclusion in stem cell tracking panels.
CD
45
RA
may contribute to define new
LSC
‐specific therapies and to monitor effects of anti‐
LSC
treatment.</abstract><doi>10.1111/bjh.13941</doi><tpages>17</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2016-04, Vol.173 (2), p.219-235 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_crossref_primary_10_1111_bjh_13941 |
| source | Wiley Online Library; Wiley Online Library Journals |
| title | CD 45 RA , a specific marker for leukaemia stem cell sub‐populations in acute myeloid leukaemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T15%3A44%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CD%2045%20RA%20,%20a%20specific%20marker%20for%20leukaemia%20stem%20cell%20sub%E2%80%90populations%20in%20acute%20myeloid%20leukaemia&rft.jtitle=British%20journal%20of%20haematology&rft.au=Kersten,%20Bas&rft.date=2016-04&rft.volume=173&rft.issue=2&rft.spage=219&rft.epage=235&rft.pages=219-235&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.13941&rft_dat=%3Ccrossref%3E10_1111_bjh_13941%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |